Citicoline in vascular cognitive impairment and vascular dementia after stroke

Jose Alvarez-Sabín1, Gustavo C Román

  • 1Neurovascular Unit, Department of Neurology, Universitat Autónoma de Barcelona, Hospital Vall d'Hebron, Barcelona, Spain.

Stroke
|December 18, 2010
PubMed

Insights

Citicoline may prevent cognitive decline following a stroke. This study found it improved attention and executive function in patients with first-ever ischemic stroke, offering a promising recovery option.

Area of Science:

  • Neurology
  • Neuroscience
  • Pharmacology

Background:

  • Cognitive decline is a common consequence of stroke, increasing dementia risk.
  • Vascular factors significantly contribute to cognitive impairment and dementia post-stroke.
  • Few pharmacological interventions target post-stroke cognitive impairment.

Purpose of the Study:

  • To evaluate the efficacy of citicoline in preventing cognitive decline after ischemic stroke.
  • To assess citicoline's impact on specific cognitive domains in stroke survivors.
  • To explore citicoline's potential as a treatment for vascular cognitive impairment and dementia.

Main Methods:

  • A 6-month clinical trial involving patients with first-ever ischemic stroke.
  • Assessment of cognitive functions including temporal orientation, attention, and executive function.
  • Evaluation of citicoline's neuroprotective and neural repair mechanisms.

Main Results:

  • Citicoline administration prevented cognitive decline in patients after ischemic stroke.
  • Significant improvements were observed in temporal orientation, attention, and executive function.
  • Citicoline demonstrated neuroprotective effects and enhanced neural repair in experimental models.

Conclusions:

  • Citicoline is a safe and promising agent for improving stroke recovery.
  • It may be beneficial for patients with vascular cognitive impairment and vascular dementia.
  • Citicoline could be indicated for Alzheimer's disease patients with cerebrovascular disease.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...